Eventide Gilead Fund Wins 2014 Lipper Fund Award

BOSTON, MA – (Marketwire, April 10, 2014) – The Eventide Gilead Fund (ETILX) was awarded the 2014 Lipper Fund Award for Best Mid-Cap Growth Fund for the three-year period, out of 336 eligible funds. The Lipper Fund Award honors the top mutual fund in each fund classification on the basis of both risk- adjusted returns and the consistency of performance over the period.

The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, a Boston-based registered investment advisor practicing values-based investing. “Eventide’s goal is high performance, values- based asset management for investors. We’re honored to receive the Lipper Award for superior performance, and proud to have generated the outperformance by investing in truly admirable companies,” commented Robin John, Eventide CEO.

Lipper Fund Awards are not intended to constitute investment advice. Rather, you should use the awards for informational purposes only.

Lipper Fund Awards are given to the highest Lipper Leader for Consistent Return for each Lipper Fund Classification for 3-, 5-, and 10-yr periods. 2014 awards are for time periods ended November 30, 2013. For additional details on Lipper Fund Award and Lipper Leader methodology, visit www.lipperweb.com.

Mutual Funds involve risk including the possible loss of principal. The Eventide Funds can invest in smaller- sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The funds can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The funds can have risk associated with a higher portfolio turnover, which could result in higher transactional costs. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

An investor should consider the Funds investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about Eventide Funds can be found in the Funds prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836) or visit www.eventidefunds.com. Eventide Funds are distributed by Northern Lights Distributors, LLC, member FINRA, which is not affiliated with Eventide Asset Management, LLC.

Fund Contact:
Jason Myhre, 877-771-EVEN (3836)

4010-NLD-4/9/2014

News › Eventide Gilead Fund Wins 2014 Lipper Fund Award

Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results.The Funds’ ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. Because of ongoing market volatility, the Funds performance may be subject to substantial short-term changes.

The Eventide Gilead Fund & Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector also carry various risks including, but not limited to, risk related to debt loads and intense competition.

Investors in the Eventide Multi-Asset Income Fund should be aware that interest rates are at historic lows and may change at any time based on government policy. In general, the price of a fixed income security falls when interest rates rise. A rise in interest rates may result in volatility and increased redemptions, which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices. Longer-term securities may be more sensitive to changes in interest rates. The intermediate-term bond portion of the Fund’s portfolio may represent 0% to 100% of the Fund’s portfolio with an average duration of between two and eight years.

The Eventide Multi-Asset Income Fund may invest in other funds. If other funds are utilized, such underlying funds are subject to investment advisory and other expenses, which will be indirectly paid by the Fund. As a result, your cost of investing in the Fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds. The Fund may invest, directly or indirectly, in “junk bonds.” Such securities are speculative investments that carry greater risks than higher quality debt securities. There are unique risks associated with REITs, MLPs, preferred stocks, convertible bonds, BDCs, and yieldcos that are covered in the Fund's prospectus and SAI. The Fund is a new mutual fund and has a limited history of operations for investors to evaluate.

An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.